Neuroprotective Effect of β-Lapachone in MPTP-Induced Parkinson's Disease Mouse Model: Involvement of Astroglial p-AMPK/Nrf2/HO-1 Signaling Pathways |
Park, Jin-Sun
(Department of Molecular Medicine, Tissue Injury Defense Research Center, School of Medicine, Ewha Womans University)
Leem, Yea-Hyun (Department of Molecular Medicine, Tissue Injury Defense Research Center, School of Medicine, Ewha Womans University) Park, Jung-Eun (Department of Molecular Medicine, Tissue Injury Defense Research Center, School of Medicine, Ewha Womans University) Kim, Do-Yeon (Department of Molecular Medicine, Tissue Injury Defense Research Center, School of Medicine, Ewha Womans University) Kim, Hee-Sun (Department of Molecular Medicine, Tissue Injury Defense Research Center, School of Medicine, Ewha Womans University) |
1 | Burton, N. C., Kensler, T. W. and Guilarte, T. R. (2006) In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 27, 1094-1100. DOI |
2 | Chen, P. C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W. and Johnson, J. A. (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc. Natl. Acad. Sci. U.S.A. 106, 2933-2938. DOI |
3 | Chen, W. F., Wu, L., Du, Z. R., Chen, L., Xu, A. L., Chen, X. H., Teng, J. J. and Wong, M. S. (2017) Neuroprotective properties of icariin in MPTP-induced mouse model of Parkinson's disease: involvement of PI3K/Akt and MEK/ERK signaling pathways. Phytomedicine 25, 93-99. DOI |
4 | Gan, L., Vargas, M. R., Johnson, D. A. and Johnson, J. A. (2012) Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. J. Neurosci. 32, 17775-17787. DOI |
5 | Gomez Castellanos, J. R., Prieto, J. M. and Heinrich, M. (2009) Red Lapacho (Tabebuiaimpetiginosa)-a global ethnopharmacological commodity? J. Ethnopharmacol. 121, 1-13. DOI |
6 | Jackson-Lewis, V. and Przedborski, S. (2007) Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2,141-151. DOI |
7 | Jakel, R. J., Townsend, J. A., Kraft, A. D. and Johnson, J. A. (2007) Nrf2-mediated protection against 6-hydroxydopamine. Brain Res. 1144, 192-201. DOI |
8 | Jo, M. G., Ikram, M, Jo, M. H., Yoo, L., Chung, K. C., Nah, S. Y., Hwang, H., Rhim, H. and Kim, M. O. (2019) Gintoin mitigates MPTP-induced loss of nigrostriatal dopaminergic neurons and accumulation of -synuclein via the Nrf2/HO-1 pathway. Mol. Neurobiol. 56, 39-55. DOI |
9 | Johnson, D. A. and Johnson, J. A. (2015) Nrf2-a therapeutic target for the treatment of neurodegenerative diseases. Free Radic. Biol. Med. 88, 253-267. DOI |
10 | Hussain, H. and Green, I. R. (2017) Lapachol and lapachone analogs: a journey of two decades of patent research (1997-2016). Expert. Opin. Ther. Pat. 27, 1111-1121. DOI |
11 | Kim, A. Y., Jeong, K. H., Lee, J. H., Kang, Y., Lee, S. H. and Baik, E. J. (2017) Glutamate dehydrogenase as a neuroprotective target against brain ischemia and reperfusion. Neuroscience 340, 487-500. DOI |
12 | Lee, E. J., Ko, H. M., Jeong, Y. H., Park, E. M. and Kim, H. S. (2015) -Lapachone suppresses neuroinflammation by modulating the expression of cytokines and matrix metalloproteinases in activated microglia. J. Neuroinflammation 12, 133. DOI |
13 | Lee, M., Ban, J. J., Chung, J. Y., Im, W. and Kim, M. (2018) Amelioration of Huntington's disease phenotypes by -lapachone is associated with increases in Sirt1 expression, CREB phosphorylation and PGC- deacetylation. PLoS ONE 9, e0195968. |
14 | Liddell, J. R. (2017) Are astrocytes the predominant cell type for activation of Nrf2 in aging and neurodegeneration? Antioxidants 6, 65. DOI |
15 | Schaffner-Sabba, K., Schmidt-Ruppin, K. H., Wehrli, W., Schuerch, A. R. and Wasley, J. W. (1984) -Lapachone: synthesis of derivatives and activities in tumor models. J. Med. Chem. 27, 990-994. DOI |
16 | Oh, G. S., Kim, H. J., Choi, J. H., Shen, A., Choe, S. K., Karna, A., Lee, S. H., Jo H. J., Yang, S. H., Kwak, T. H., Lee, C. H., Par, R. and So, H. S. (2014) Pharmacological activation of NQO1 increases levels and attenuates cisplatin-mediated acute kidney injury in mice. Kidney Int. 85, 547-560. DOI |
17 | Park, J. S., Lee, Y. Y., Kim, J., Seo, H. and Kim, H. S. (2016) -Lapachone increases phase II antioxidant enzyme expression via NQO1-AMPK/PI3K-Nrf2/ARE signaling in rat primary astrocytes. Free Radic. Biol. Med. 97, 168-178. DOI |
18 | Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A. E. and Lang, A. E. (2017) Parkinson disease. Nat. Rev. Dis. Primers 3, 17013. DOI |
19 | Przedborski, S. (2017) The two-century journey of Parkinson disease research. Nat. Rev. Neurosci. 18, 251-259. DOI |
20 | Puspita, L., Chung, S. Y. and Shim, J. W. (2017) Oxidative stress and cellular pathologies in Parkinson's disease. Mol. Brain 10, 53. DOI |
21 | Tieu, K. (2011) A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb. Perspect. Med. 1, a009316. DOI |
22 | Zhang, M., An, C., Gao, Y., Leak, R. K., Chen, J. and Zhang, F. (2013) Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog. Neurobiol. 100, 30-47. DOI |
23 | Vargas, M. R., Johnson, D. A., Sirkis, D. W., Messing, A. and Johnson, J. A. (2008) Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J. Neurosci. 28, 13574-13581. DOI |
24 | Vargas, M. R. and Johnson, J. A. (2009) The Nrf2-ARE cytoprotective pathway in astrocytes. Expert Rev. Mol. Med. 11, e17. DOI |
25 | Xu, J., Wagoner, G., Douglas, J. C. and Drew, P. D. (2013) -Lapachone ameliorization of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 254, 46-54. DOI |
26 | Yamada, M., Oligino, T., Mata, M., Goss, J. R., Glorioso, J. C. and Fink, D. J. (1999) Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc. Natl. Acad. Sci. U.S.A. 96, 4078-4083. DOI |